Stock BRPA NRX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.55 USD +0.28% Intraday chart for NRx Pharmaceuticals, Inc. +18.33% -22.83%
Apr. 18 NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq MT
Apr. 18 Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
AQ
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
AQ
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100
AQ
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
AQ
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
PR
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
PR
UPDATE, NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
AQ
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
PR
NRx Pharmaceutical's Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
AQ
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
PR
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
PR
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
PR
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
PR
NRx Pharmaceuticals Initiates Strategy to Combat Short Sales
AQ
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
PR
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
PR
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
AQ
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
PR
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRPA Stock
  4. News NRx Pharmaceuticals, Inc.
  5. Press Releases